Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$126.63 ▲ +4.03
(+3.29%)
MKT CAP: $10.19B • VOL: 1.59M
52W L $56 52W H $130
KYMR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $39.2M | $47.1M | $78.6M |
| YoY Revenue Growth % | -16.7% | -40.1% | — |
| Gross Profit | $0 | $0 | — |
| Gross Margin % | 0.0% | 0.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$349.4M | -$261.6M | -$165.5M |
| Operating Margin % | -891.1% | -555.8% | -210.6% |
| Net Income (GAAP) | $311.4M | $223.9M | $147.0M |
| EBITDA (Normalized) | -$348.2M | -$251.4M | -$162.7M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$232.9M | -$194.5M | -$102.8M |
| Capital Expenditures (CapEx) | $1.4M | $12.8M | $3.5M |
| Free Cash Flow (FCF) | -$234.3M | -$207.3M | -$106.4M |
| FCF Margin % | -597.6% | -440.5% | -135.3% |
| Return on Invested Capital (ROIC %) | -21.3% | -26.5% | -3.9% |
| Cash & Short-Term Equivalents | $357.0M | $120.3M | — |
| Total Debt (Short + Long Term) | $73.4M | $64.1M | $1.31B |
| Total Stockholders' Equity | $1.58B | $835.6M | $2.69B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR KYMR.